Cited by 245Neurotransmitter Receptor Influence on BehaviorTreatment of Major DepressionNeural and Behavioral Psychology Studies

The role of the brain reward system in depression

Naranjo, Claudio A., Tremblay, Lescia K., Busto, Usoa E.·2001·Progress in Neuro-Psychopharmacology and Biological Psychiatry

Abstract

The goal of this review is to familiarize the reader about the potential involvement of the brain reward system (BRS) in symptoms of Major Depressive Disorder (MDD). The authors introduce a novel approach to study the pathophysiology of MDD that includes pharmacological probing of BRS pathways (e.g. d-amphetamine, hydromorphone) together with an elicited and measurable behavioral component (e.g. pleasant effects, increased energy, altered cognition). To this date, the major focus of MDD pathophysiology studies has been to characterize biological differences between healthy subjects and depressed patients such as alteration in the monoaminergic and endocrine systems. The relative importance of the various biological changes has not been elucidated, that is, linking these with specific behavioral manifestations in MDD have rarely been attempted. One core symptom of MDD is a decreased experience of pleasure or interest in previously enjoyed activities (i.e. anhedonia) such as work or hobbies, and is accompanied by decreased motivation or drive. The BRS consists of the neural pathways involved in eliciting rewarding experiences in animals and humans. The hypothesis is that altered BRS function may be an underlying brain mechanism of the loss of pleasure/interest experienced in MDD, and will be manifested through an altered response to a BRS probe. The authors have examined BRS function in MDD by introducing a pharmacological probe (i.e. d-amphetamine/d-amph). Amphetamine is defined as a probe due to its ability to release dopamine within major components of the BRS (i.e. the mesocorticolimbic dopamine system.) In addition to the objective pharmacological effects (e.g. altered heart rate), BRS probes like d-amph elicit reliable and measurable behavior, that is, the hedonic effects. A review of the neurobiology of MDD, the BRS, the rationale for implicating the BRS in depressive symptoms, and preliminary data, are presented in this article.

Integrity signals

Registry

Crossref · 10.1016/s0278-5846(01)00156-7

Cites

271 of 271 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • These neurotransmitter systems play key roles in neurotransmission, brain maturation, cortical organisation, and behaviours including social and repetitive behaviour.

    “These systems play key roles in neurotransmission, brain maturation, cortical organisation and behaviours (including social behaviour and repetitive behaviour) [180,181,182,183,184].”

    From Vitamin D and Autism Spectrum Disorder: A Literature Review (2016) · cites this paper as [182]

  • Multiple lines of evidence suggest an involvement of dysregulated neurotransmitter systems (serotonergic, oxytocinergic, and dopaminergic) in autism.

    “Multiple lines of evidence suggest an involvement of dysregulated neurotransmitter systems (serotonergic, oxytocinergic and dopaminergic systems) in autism.”

    From Vitamin D and Autism Spectrum Disorder: A Literature Review (2016) · cites this paper as [182]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Naranjo, C. A., Tremblay, L. K., & Busto, U. E.
Affiliations
Sunnybrook Health Science Centre (CA)
Corresponding author
Naranjo, Claudio A.
Venue
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Publisher
Elsevier BV
Published
2001-05
Volume
25
Issue
4
Pages
781-823
ISSN
0278-5846 (ISSN-L)
OpenAlex
W2040295810
Cited by
245
References
271
Citations by year
2025: 7 · 2024: 5 · 2023: 3 · 2022: 6 · 2021: 7 · 2020: 7 · 2019: 9 · 2018: 13 · 2017: 11 · 2016: 10 · 2015: 8 · 2014: 7 · 2013: 13 · 2012: 13
FWCI
0.77
Type
journal article
Language
en
Open access
closed
Locations
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Neural and Behavioral Psychology Studies
Keywords
brain reward system, major depressive disorder, anhedonia, dopamine, mesocorticolimbic dopamine system, amphetamine challenge, hydromorphone, motivation, depression pathophysiology
MeSH terms
Amphetamine, Central Nervous System Stimulants, Animals, Brain, Brain Chemistry, Depressive Disorder, Humans, Reward

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review